Emmaus Life Sciences Inc. is counting on new statistical analyses and secondary endpoints to resolve FDA's concerns about the single Phase III trial submitted with the new drug application for the company's pharmaceutical-grade L-glutamine (PGLG) to treat sickle cell disease.
The product could be a landmark in a disease with significant unmet need – Emmaus emphasizes that PGLG would be...







